###### Strengths and limitations of this study

-   We tracked subjects for a period longer than 1000 days after the initial schizophrenia diagnosis day.

-   This is the first study investigating the relationship between antipsychotics and risk of chronic kidney disease (CKD) among inpatients with schizophrenia.

-   The measurement of exposure, use of antipsychotic drugs, can only be estimated by the existing dataset we used.

-   Using the existing dataset without personal identification, we cannot investigate all risk factors in the study.

-   The risk of CKD in patients with schizophrenia deserves further investigation. Besides, the study of CKD risk for patients with schizophrenia might need longer tracking duration.

Introduction {#s1}
============

Schizophrenia is a chronic mental illness with lifetime prevalence rate around 1%.[@R1] Patients with schizophrenia have been shown to have an excess mortality, being two or three times as high as that in the general population.[@R3] Cardiovascular diseases have an increased prevalence among patients with schizophrenia.[@R6] Metabolic syndrome, a collection of visceral adiposity (measured by waist size), high-fasting glucose, increased blood pressure, elevated triglyceride levels and low high-density lipoprotein cholesterol levels,[@R7] also seems to be a vital health problem to patients with schizophrenia.[@R8] Furthermore, patients with schizophrenia are liable to develop diabetes mellitus (DM)[@R1] and chronic kidney diseases (CKDs).[@R11]

The introduction of second-generation antipsychotics (SGAs) in the early 1990s was initially associated with better quality of life, lower rate of relapse and better tolerability than first-generation antipsychotics (FGAs).[@R12] However, the superiority of SGAs has been criticised by subsequent studies.[@R15] For example, the association between weight gain and use of SGAs, clozapine in particular, has been reported.[@R17]

More recent studies confirmed the above finding regarding the concern of using SGA medications. A study using the National Health Insurance Research Database in Taiwan[@R18] found that use of clozapine, quetiapine, olanzapine, zotepine and risperidone was associated with the increased risk of pneumonia. A nationwide German/Austrian Diabetes Survey, which recruited 60 162 teenagers with type 1 DM, demonstrated that subjects treated with SGAs, risperidone in particular, showed higher body mass index.[@R19] A national study[@R20] conducted in the USA compared 107 551 youths using SGAs with 1 221 434 youths who do not. The risk for incident DM was increased in youths taking SGAs. The risk was higher among those using ziprasidone and aripiprazole. However, the risk for incident type 2 DM was not associated with newer SGAs, quetiapine and olanzapine.

DM was one of risk factors to develop CKD.[@R21] Besides, schizophrenia has been shown to be associated with an increased risk of CKD in a nationwide study in Taiwan.[@R11] Therefore, we consider CKD to be included as an outcome variable, too. A population-based, nested case--control study is carried out here by applying the large national psychiatric database, the Psychiatric Inpatient Medical Claims database. Meanwhile, to provide a comprehensive picture of the risk of using antipsychotics, we compare people who used both first-generation antipsychotics (FGAs) and SGAs, people who use only SGAs with those who used only FGA drugs in our study.

Methods {#s2}
=======

Study subjects {#s2a}
--------------

Taiwan started a single-payer National Health Insurance programme on 1 March 1995. The National Health Insurance reimbursement claims data have been transferred to and managed by the National Health Research Institute in Taiwan since 1996. The database includes medical claim files representative of the entire population in Taiwan. All investigators signed an agreement that guarantees patient confidentiality before using the data. We used the Psychiatric Inpatient Medical Claims database, a subset of the National Health Insurance Research Database, comprising a cohort of patients hospitalised for psychiatric disorders between 2000 and 2013 (n=267 807). The database included patients with at least one psychiatric inpatient record and one discharge diagnosis of mental disorders coded by the International Classification of Diseases, Ninth Revision (ICD-9) codes 290--319. The database includes patients' demographic characteristics, diagnoses, medical expenditures and prescription claims data.[@R22] Each prescription record contains type of medication, dosage, time of prescription and duration of drug supply. Information which could be used to identify beneficiaries and medical care providers were scrambled by the Bureau of National Health Insurance.[@R23]

We enrolled patients with at least one psychiatric admission between 2000 and 2013 but no psychiatric admissions between 1996 and 1999 (n=13 644). The inclusion criteria for the study cohort was that one's diagnosis at each discharge fulfilled the principal diagnosis of schizophrenia (ICD-9 code 295.\*\*) if a patient had several psychiatric admissions. The age of patients at first admission was restricted to 18--65 years.

Case and control definition {#s2b}
---------------------------

In this study, we conducted a nested case--control study derived from the cohort. Patients with CKD (ICD-9 codes 582, 583, 585, 586, 588) requiring hospitalisation or three outpatient visits were selected as cases (n=3411). The date of first hospitalisation for CKD or the third outpatient visit was defined as the index date. The diagnosis of CKD follows the criteria of 'Kidney Disease: Improving Global Outcomes' in Taiwan. CKD is defined as a kidney damage as albumin-to-creatinine ratio \>30 mg/g in two of three spot urine specimens or glomerular filtration rate \<60 mL/min/1.73 m^2^ for 3 months or more. For each case, three matched control subjects were randomly selected from the same patients with schizophrenia who have not been diagnosed with CKD before the index date. Control subjects were matched to the patients for age diagnosed with schizophrenia, gender and the year diagnosed with schizophrenia. Each control was assigned the index date of the corresponding case. The patients diagnosed with CKD before the schizophrenia diagnosis date were excluded.

Measurement of exposure {#s2c}
-----------------------

The data of antipsychotic drug use were derived from the prescription files. The duration of treatment was calculated using the dispensed number of units and the dosing regimen for each patient. SGA drugs used in our study included clozapine, olanzapine, quetiapine, zotepine, risperidone, amisulpride, ziprasidone, aripiprazole and paliperidone. FGA drugs used in our study included chlorpromazine, levomepromazine, fluphenazine, perphenazine, trifluoperazine, thioridazine, pipotiazine, haloperidol, moperone, flupentixol, clopenthixol, chlorprothixene, pimozide, loxapine, sulpiride, clotiapine and penfluridol. Because this study focused on the associations between the individual SGA drug and the risk of CKD, all FGA drugs were grouped together in the data analysis. The follow-up period is from the schizophrenia diagnosis date to the index date.

Covariates {#s2d}
----------

Age, gender and the duration of schizophrenia were controlled by the matching process of the study design.

Statistical analysis {#s2e}
--------------------

For the comparisons of demographic between cases and controls, t test was used for continuous variables and χ^2^ tests for discrete variables. Univariate and multivariable conditional logistic regressions were used to estimate the associations between the exposure to antipsychotic use and risk of CKD. Comorbidity factors, such as DM, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, hypertension and obesity were entered into adjusted model. ORs with 95% CIs were calculated. A p value of 0.05 was considered significant.

Patient and public involvement {#s2f}
------------------------------

We used the National Health Insurance reimbursement claims data in Taiwan.

Results {#s3}
=======

A total of 3411 patients with CKD and 10 233 matched controls were enrolled in this study. Age, gender and the duration of schizophrenia of the cases and control subjects were well matched. The characteristics of patients with CKD and matched controls were compared and showed in [table 1](#T1){ref-type="table"}. The cases were more likely to have comorbid conditions than controls ([table 1](#T1){ref-type="table"}).

###### 

Basic characteristics of the study population

  ------------------------------------------------------------------------
  Characteristic                       Cases\           Controls\
                                       (n=3411) n (%)   (n=10 233) n (%)
  ------------------------------------ ---------------- ------------------
  Age (mean±SD years)                  41.1±10.2        41.1±10.2

  Male                                 1871 (54.9)      5613 (54.9)

  Follow-up duration (mean±SD years)   7.71±4.71        7.71±4.71

  Comorbidities                                         

   Diabetes mellitus\*                 1299 (38.1)      1006 (9.8)

   Congestive heart failure\*          207 (6.1)        86 (0.8)

   Myocardial infarction\*             41 (1.2)         23 (0.2)

   Stroke\*                            220 (6.5)        195 (1.9)

   Hyperlipidaemia\*                   502 (14.7)       433 (4.2)

   Hypercholesterolaemia\*             111 (3.3)        90 (0.9)

   Hypertriglyceridaemia\*             86 (2.5)         62 (0.6)

   Hypertension\*                      1232 (36.1)      1147 (11.2)

   Obesity\*                           49 (1.4)         37 (0.4)
  ------------------------------------------------------------------------

\*P\<0.0001.

More than 85% subjects were received both FGA and SGA medications. Case and control groups separately include 3082 (90.4%) and 8827 (86.3%) subjects ([table 2](#T2){ref-type="table"}). Taking patients using FGA only as reference group, the adjusted ORs (95% CI) for those who used no FGA and no SGA, SGA alone, both FGA and SGA were 0.53 (0.13--2.21), 1.06 (0.65--1.74), 1.28 (1.11--1.47), respectively ([table 2](#T2){ref-type="table"}). Patients used both FGA and SGA have significant greater risk than patients used FGA only (p=0.0009) ([table 2](#T2){ref-type="table"}).

###### 

Comparison of crude and adjusted OR for CKD among types of antipsychotics by conditional logistic regression

  Drug used        CKD cases (n=3411)   Controls (n=10 233)   OR (95% CI)           P value    AOR\* (95% CI)        P value
  ---------------- -------------------- --------------------- --------------------- ---------- --------------------- ---------
  No FGA, no SGA   3                    17                    0.76 (0.22 to 2.59)   0.6570     0.53 (0.13 to 2.21)   0.3857
  FGA alone        300                  1278                  1                                1                     ---
  SGA alone        26                   102                   1.10 (0.70 to 1.72)   0.6920     1.06 (0.65 to 1.74)   0.8068
  Combination      3082                 8827                  1.50 (1.32 to 1.71)   \<0.0001   1.28 (1.11 to 1.47)   0.0009

\*Adjusted for diabetes mellitus, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, hypertension and obesity.

AOR, adjusted OR; CKD, chronic kidney disease; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic.

With the adjustment of comorbidity factors, the analysis results showed that greater risks of CKD for patients who received SGA than patients who did not receive as the reference group. Especially, patients cumulatively used SGA 90--180 days and more than 1000 days have 42% and 30% significantly higher odds of developing CKD compared with the reference group (adjusted OR (95% CI)=1.42 (1.06 to 1.91), 1.30 (1.13 to 1.51)) ([table 3](#T3){ref-type="table"}). Patients who used olanzapine, quetiapine, zotepine or risperidone all displayed greater odds of developing CKD than the reference group. Patients with quetiapine exposure have statistically significant higher risk than the reference group.

###### 

Overall cumulative period of using SGAs

  ---------------------------------------------------------------------------------------------------------------------------------------
  Period of SGA use                   CKD cases (n=3411)   Controls\    OR (95% CI)           P value    AOR\* (95% CI)        P value
                                                           (n=10 233)                                                          
  ----------------------------------- -------------------- ------------ --------------------- ---------- --------------------- ----------
  Cumulative SGA use                                                                                                           

   Non-users                          303                  1304         1                                1                     

   0\<period≤ 90                      177                  552          1.38 (1.12 to 1.71)   0.0026     1.20 (0.95 to 1.51)   0.1247

   90\<period≤ 180                    92                   241          1.65 (1.26 to 2.16)   0.0003     1.42 (1.06 to 1.91)   0.0208

   180\<period≤ 1000                  409                  1271         1.39 (1.17 to 1.64)   0.0001     1.19 (0.99 to 1.43)   0.0654

   1000\>period                       2430                 6865         1.53 (1.34 to 1.75)   \<0.0001   1.30 (1.13 to 1.51)   0.0004

  Cumulative clozapine use (days)                                                                                              

   Non-users                          2318                 7215         1                                1                     

   0\<period≤ 90                      183                  351          1.63 (1.35 to 1.96)   \<0.0001   1.48 (1.20 to 1.81)   0.0002

   90\<period≤180                     49                   140          1.09 (0.79 to 1.52)   0.6057     0.91 (0.63 to 1.32)   0.6281

   180\<period≤1000                   178                  549          1.01 (0.85 to 1.20)   0.9091     0.94 (0.77 to 1.14)   0.5099

   1000\>period                       683                  1978         1.08 (0.98 to 1.19)   0.1456     1.14 (1.02 to 1.27)   0.0181

  Cumulative olanzapine use (days)                                                                                             

   Non-users                          2046                 6465         1                                1                     

   0\<period≤90                       396                  1018         1.23 (1.09 to 1.40)   0.0012     1.18 (1.02 to 1.35)   0.0225

   90\<period≤180                     156                  344          1.44 (1.18 to 1.75)   0.0003     1.37 (1.11 to 1.70)   0.0039

   180\<period≤1000                   401                  1038         1.22 (1.08 to 1.39)   0.0017     1.15 (1.00 to 1.32)   0.0561

   1000\>period                       412                  1368         0.95 (0.85 to 1.08)   0.4401     1.05 (0.92 to 1.19)   0.4954

  Cumulative quetiapine use (days)                                                                                             

   Non-users                          1669                 6198         1                                1                     

   0\<period≤90                       399                  967          1.54 (1.35 to 1.75)   \<0.0001   1.36 (1.19 to 1.57)   \<0.0001

   90\<period≤180                     147                  356          1.54 (1.26 to 1.88)   \<0.0001   1.27 (1.02 to 1.58)   0.0358

   180\<period≤1000                   534                  1180         1.69 (1.50 to 1.89)   \<0.0001   1.48 (1.30 to 1.68)   \<0.0001

   1000\>period                       662                  1532         1.61 (1.45 to 1.79)   \<0.0001   1.44 (1.28 to 1.62)   \<0.0001

  Cumulative zotepine use (days)                                                                                               

   Non-users                          2292                 7375         1                                1                     

   0\<period≤90                       319                  743          1.38 (1.20 to 1.59)   \<0.0001   1.26 (1.08 to 1.47)   0.0038

   90\<period≤180                     120                  265          1.46 (1.17 to 1.82)   0.0008     1.27 (0.99 to 1.63)   0.0592

   180\<period≤1000                   310                  770          1.30 (1.13 to 1.49)   0.0003     1.16 (1.00 to 1.36)   0.0572

   1000\>period                       370                  1080         1.11 (0.97 to 1.26)   0.1240     1.00 (0.87 to 1.15)   0.9854

  Cumulative risperidone use (days)                                                                                            

   Non-users                          896                  3056         1                                1                     

   0\<period≤90                       396                  1078         1.26 (1.09 to 1.44)   0.0012     1.14 (0.98 to 1.33)   0.0927

   90\<period≤180                     207                  511          1.39 (1.16 to 1.66)   0.0003     1.26 (1.03 to 1.53)   0.0220

   180\<period≤1000                   733                  2028         1.24 (1.10 to 1.38)   0.0002     1.12 (0.99 to 1.26)   0.0845

   1000\<period                       1179                 3560         1.13 (1.03 to 1.25)   0.0148     1.10 (0.99 to 1.23)   0.0756
  ---------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for diabetes mellitus, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, hypertension and obesity.

AOR, adjusted OR; CKD chronic kidney disease; SGA, second-generation antipsychotic.

Discussion {#s4}
==========

We found that the risks for CKD for those who used SGAs longer cumulatively were higher than those who did not. In addition, those who used only FGAs and those who used both SGAs and FGAs seemed to have lower risk for CKD.

Also using the dataset of Taiwan National Health Insurance, Tzeng *et al*[@R11] found that neither FGAs nor SGAs increased the risk of CKD. However, the study design of Tzeng *et al* and ours varied a lot. First, we focused on in patients while Tzeng *et al* recruited patients with a first-time diagnosis of schizophrenia. Second, subjects of Tzeng *et al* were tracked for 3 years or the end of 2010 from the initial diagnosis date until the date of CKD diagnosis. We tracked subjects for longer period with one group tracked for 180--1000 days and another for period longer than 1000 days.

The introduction ofSGAs in the early 1990s was initially shown better quality of life, lower rate of relapse and better tolerability than FGAs for patients of schizophrenia[@R13] but has been criticised by other studies.[@R15] The risk of pneumonia in inpatients with schizophrenia was examined using the National Health Insurance Research Database in Taiwan from 2000 to 2008.[@R18] They found that the current use of clozapine, one kind of SGAs, was associated with a dose-dependent increase in the risk of pneumonia for inpatients with schizophrenia. In addition, other kinds of SGAs, including quetiapine, olanzapine, zotepine and risperidone were associated with increased risk of pneumonia while no clear dose-dependent relationship was found. They suggested that patients with schizophrenia who used these antipsychotics were to be monitored for pneumonia. Our study further suggests that inpatients with schizophrenia were being monitored for CKD, since we found that the risks for CKD were higher for those who used SGAs longer cumulatively than those who did not. Similar to the findings of Kuo *et al*, we did not see dose-dependent relationship SGAs and risk of CKD.

The increasing prevalence of end-stage renal disease (ESRD) has been a global challenge. In the USA, CKDs are the nation's ninth leading cause of death.[@R24] In Taiwan, CKDs have been the eighth leading cause of death since 1997 and was still the 10th leading cause of death recently.[@R25] Meanwhile, the high prevalence of CKD might contribute to the high prevalence of ESRD in Taiwan.[@R26] Our finding that inpatients with schizophrenia who used SGAs longer have higher risks for CKD than those who did not reminds this population being monitored for CKD.

Some limitations need to be considered in the current study. First, because our data source is from a claim data set, it is hard to know how much medication each patient really took. Second, we cannot include variables not captured in the claimed database, such as patients' lifestyle and family history. However, the current study suggests a further study on the relationship between using SGAs and risk of CKD.
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